CERS - Cerus and Shandong Zhongbaokang partner to form joint venture in China

Cerus (CERS) and Shandong Zhongbaokang Medical Implements form joint venture to develop, manufacture and commercialize the INTERCEPT Blood System for platelets and red blood cells in China.The JV, which will be named "Cerus ZBK Biomedical", will be headquartered in Zibo, Shandong Province in eastern China.Under the terms of the JV agreement, Cerus and ZBK are the sole shareholders in the venture, with Cerus owning a majority (51%) of the entity.Cerus anticipates that it will consolidate the results of Cerus ZBK Biomedical in its consolidated financial statements.

For further details see:

Cerus and Shandong Zhongbaokang partner to form joint venture in China